Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Steve McGuire

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
Positively Aware : the Monthly Journal of the Test Positive Aware Network|September 4, 2003
Dealing with Sustiva side effectsSteve McGuire
Positively Aware : the Monthly Journal of the Test Positive Aware Network|July 18, 2003
HIV treatment series. Part 4 of 4. Decisions, decisions--starting or switching anti-HIV therapySteve McGuire
Positively Aware : the Monthly Journal of the Test Positive Aware Network|December 18, 2002
Metabolic toxicities and HIVSteve McGuire
Neuropharmacology|July 18, 2016
An evaluation of istradefylline treatment on Parkinsonian motor and cognitive deficits in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated macaque modelsWai Kin D Ko, Sandrine M Camus, Qin Li, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|March 11, 2014
Combined fenobam and amantadine treatment promotes robust antidyskinetic effects in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned primate model of Parkinson's diseaseWai Kin D Ko, Elsa Pioli, Qin Li, et al.
Experimental Neurology|July 29, 2009
Sleep disorders in Parkinson's disease: the contribution of the MPTP non-human primate modelQuentin Barraud, Virginie Lambrecq, Claude Forni, et al.
Plos One|October 23, 2010
Neuroanatomical study of the A11 diencephalospinal pathway in the non-human primateQuentin Barraud, Ibrahim Obeid, Incarnation Aubert, et al.
The Journal of Pharmacology and Experimental Therapeutics|February 24, 2004
S32504, a novel naphtoxazine agonist at dopamine D3/D2 receptors: II. Actions in rodent, primate, and cellular models of antiparkinsonian activity in comparison to ropiniroleMark J Millan, Benjamin Di Cara, Michael Hill, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|May 15, 2018
Inhaling xenon ameliorates l-dopa-induced dyskinesia in experimental parkinsonismJérôme Baufreton, Tomislav Milekovic, Qin Li, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
Positively Aware : the Monthly Journal of the Test Positive Aware Network|September 4, 2003
Dealing with Sustiva side effectsSteve McGuire
Positively Aware : the Monthly Journal of the Test Positive Aware Network|July 18, 2003
HIV treatment series. Part 4 of 4. Decisions, decisions--starting or switching anti-HIV therapySteve McGuire
Positively Aware : the Monthly Journal of the Test Positive Aware Network|December 18, 2002
Metabolic toxicities and HIVSteve McGuire
Neuropharmacology|July 18, 2016
An evaluation of istradefylline treatment on Parkinsonian motor and cognitive deficits in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated macaque modelsWai Kin D Ko, Sandrine M Camus, Qin Li, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|March 11, 2014
Combined fenobam and amantadine treatment promotes robust antidyskinetic effects in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned primate model of Parkinson's diseaseWai Kin D Ko, Elsa Pioli, Qin Li, et al.
Experimental Neurology|July 29, 2009
Sleep disorders in Parkinson's disease: the contribution of the MPTP non-human primate modelQuentin Barraud, Virginie Lambrecq, Claude Forni, et al.
Plos One|October 23, 2010
Neuroanatomical study of the A11 diencephalospinal pathway in the non-human primateQuentin Barraud, Ibrahim Obeid, Incarnation Aubert, et al.
The Journal of Pharmacology and Experimental Therapeutics|February 24, 2004
S32504, a novel naphtoxazine agonist at dopamine D3/D2 receptors: II. Actions in rodent, primate, and cellular models of antiparkinsonian activity in comparison to ropiniroleMark J Millan, Benjamin Di Cara, Michael Hill, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|May 15, 2018
Inhaling xenon ameliorates l-dopa-induced dyskinesia in experimental parkinsonismJérôme Baufreton, Tomislav Milekovic, Qin Li, et al.
Pageof 1